African-American men have the highest incidence and mortality from prostate 
INTRODUCTION
Extensive prior work has explored socioeconomic contributions to prostate cancer disparities, however our knowledge of the extent to which molecular and genetic mechanisms may also contribute to prostate cancer disparities has been limited (1) (2) (3) (4) (5) (6) . The notion that somatic genetic factors may influence tumor biology differentially across distinct ancestral backgrounds is exemplified by high EGFR mutation rates in patients of Asian ancestry with non-small cell lung adenocarcinoma (up to 50% of patients), compared to patients of European ancestry (10-15% of cases) (7) . Large-scale genomic characterization studies are predominated by tumor samples from patients of European ancestry (8) . While of immense value, the limited racial and ethnic diversity of these studies may preclude the detection of genomic events and patterns that are unique or enriched in underrepresented groups. For example, large-scale studies such as The Cancer Genome Atlas (TCGA) have examined the genomic landscape of primary prostate cancer and have been confined mainly to men of European ancestry (81.1%, 270/333) (9) (10) (11) . In particular, African-American men, who have a 1.4-fold higher incidence and 2.4-fold higher mortality rate from prostate cancer compared to nonHispanic whites, have been underrepresented in most systematic studies of prostate cancer performed to date (10) (11) (12) . We hypothesized that differences in mutational events in African-American prostate cancers may in part underlie these disparities in outcomes. We also reasoned that the power to discover novel cancer genes might increase through inclusion of diverse ancestral backgrounds in large-scale cancer genome studies. To test these hypotheses, we performed whole exome sequencing on a discovery set of 102 localized primary prostate tumors and matched normal controls from a cohort of African-American men and performed targeted sequencing on an extension set of 90 primary prostate tumors.
RESULTS

We focused on intermediate and high-risk prostate cancers corresponding to
Gleason grades 7 and higher, or pathologic stage pT2a -pT3c (Supplemental Table 1 and 2). Exome sequencing identified 3059 somatic mutations, corresponding to a median of 7 silent and 23 non-silent mutations per tumor (range: 0-19 silent; 4-47 nonsilent). The median mutation rate for this cohort was ~0.83 mutations/Mb (range: 0.11-1.75), similar to mutation rates in exome sequencing cohorts of primary prostate cancer drawn predominantly from men of European ancestry (10, 11) .
Overall, the majority of tumors from African-American (AA) men do not harbor recurrent mutations in known cancer driver genes. Instead, most AA prostate cancers harbor somatic copy number alterations (SCNA) that are characteristic of those seen in other published cohorts ( Figure 1 and Supplemental Figure 1A ) (11, 13) . However, the overall frequencies of SCNAs appear to be lower in this AA Figure 2) . Given that the TCGA data set comprises higher frequencies of Gleason 8 and higher tumors in comparison to the AAPC cohort, these copy number differences were less pronounced when stratified by
Gleason score yet persisted at certain loci (Supplemental Table 3 and Supplemental In the AAPC cohort, a focused germline analysis for pathogenic mutations in genes in the DNA repair pathway revealed four patients with germline mutations in BRCA1 (with a concomitant hemizygous BRCA1 deletion), CHEK2 and ATM for an overall prevalence of 3.9% (Supplemental Table 4 ) (16) .
In the analysis of somatic mutations, we identified three genes (SPOP, ERF, FOXA1) wherein recurrent base mutations reached statistical significance in the discovery cohort (FDR q < .1; Figure 1 ; Supplemental Table 5 ) (17) . Of the significantly mutated genes, SPOP and FOXA1 have previously been identified as drivers in primary prostate cancer; however, ERF has not been implicated in this setting (10, 11) . ERF is a member of the ETS transcription factor family and therefore was of interest given the prominent role that ETS transcription factor rearrangements play in prostate cancer (18) . Of the five nonsynonymous ERF mutations present in our discovery cohort, three were loss-of-function events (R183*, K91fs, R218*) and another, which occurred within the ETS DNA-binding domain (Y89C), was predicted to be a damaging event by Polyphen-2 analysis (19) . In order to determine whether ERF mutations led to decreased ERF expression, we tested whether ERF mutants in prostate tumors from the AAPC cohort showed loss of ERF mRNA expression. We used RNA in situ hybridization (ISH) to show that ERF mutants from the AAPC cohort were associated with a significant loss of ERF mRNA expression ( Using GISTIC analysis to examine significant somatic copy number alterations, we also noted that a focal deletion occurred at chr19q13.2 harboring a number of genes including ERF and a known tumor suppressor, CIC, capicua transcriptional repressor (Supplemental Table 6 ) (14) . This peak represented three hemizygous copy number losses (~3%) of ERF in our exome discovery cohort ( Figure 2D ). These three patients had tumors with higher risk features: Gleason 8, pT3b; Gleason 8, pT3b with PSA of 42.3; and Gleason 7, pT2c with PSA of 12.8; two of these patients had biochemical recurrences. We verified copy number loss of ERF in an AAPC tumor using fluorescence in situ hybridization (FISH) ( Figure 2E-F Table 9 ). Tumor-normal pairs from this additional AA prostate cancer cohort were sequenced at high coverage (mean target coverage: tumor 335x, normal 348x; Supplemental Methods). In the extension cohort, we identified five additional nonsynonymous ERF mutations, three of which were predicted loss-offunction frameshift mutations ( Figure 3A and Supplemental Table 10 ). In total, the prevalence of ERF mutations in the discovery and extension AA primary prostate cancer cohorts was 5.2% (10/192) . We validated by Fluidigm array 7 of 7 of the ERF mutations that we were able to evaluate (Supplemental Figure 6) . Thus, ERF is recurrently mutated in primary prostate cancer in AA men.
While ERF was found to be a significantly mutated gene in the AAPC cohort, it did not reach statistical significance in the TCGA cohort (n=333) ( Figure 3B ) (11 Figure 7 and 8B-C) (22, 23 ). An updated analysis of genomic data from a cohort of CRPC cases shows that ERF is recurrently mutated at a frequency of ~3% (8/269) and undergoes copy number loss (hemizygous or homozygous) at a frequency of ~17.5% (47/269) (Supplemental Figure 8C) (22) . We also examined prostate cancer cell line data from the CCLE and COSMIC databases and found that ERF is mutated in one out of six prostate cancer cell lines (DU-145; p.A132S) (24, 25) .
We next asked whether alterations in ERF might be associated with more aggressive disease. ERF copy number loss was associated with a number of aggressive Table 12 ). Overall, these data raise the possibility that ERF mutations and deletions may be linked to more aggressive forms of prostate cancer.
ERF was first characterized as an ETS and Ras tumor suppressor protein with a transcriptional repressor function (26, 27) . In addition to prostate cancer, mutations in ERF occur in other tumor types at similar frequencies: stomach adenocarcinoma (~4%), colorectal adenocarcinoma (~4%), and Ewing Sarcoma (~3%), which is also notably driven by a common ETS rearrangement, EWS-FLI (28) (29) (30) . We asked whether ERF might function as a tumor suppressor in prostate cancer cells. Using We next asked whether the ERF KD signature could be associated with a more aggressive phenotype in prostate cancer. We tested whether the ERF KD gene signature was also correlated with features of aggressive prostate cancer in the TCGA dataset and found that higher Gleason scores correlated with the ERF KD gene signature (Supplemental Figure 17B) .
In an unbiased pathway analysis of cell lines from the CCLE, we found an androgen signaling (AR) signature (NELSON_RESPONSE_TO_ANDROGEN_UP) as the top correlated signature with respect to the ERF KD signature_UP (Supplemental Figure   18 ) (34). We projected this ERF KD signature into the RNA sequencing datasets generated from tumor samples in cohorts of primary prostate cancer (TCGA) and castration-resistant prostate cancer (CRPC) (11, 22) . We found that AR signatures were correlated with the ERF KD signature_UP in the TCGA and CRPC datasets ( Figure 4C ) (35) . These data suggest that AR signatures are correlated with the transcriptional program of ERF knockdown and that loss of ERF is associated with a transcriptional program that can mimic ETS activation and may impinge on androgen signaling. To test the hypothesis that ERF loss may promote androgen signaling, we used the CRISPR/Cas9 system to target the ERF coding sequence in prostate cancer cells (36) . We showed that loss of ERF is associated with an increase in androgen-dependent growth ( Figure 4D ).
Research. We also investigated other genes that were recurrently mutated but did not reach statistical significance in the AAPC discovery cohort. Y-box binding protein 1 (YBX1) (K81T, R244*, N76S), was mutated three times and has been implicated as an oncogene in prostate cancer but had not been previously identified as recurrently mutated in any prostate cancer cohorts (37) . We identified missense mutations in the steroid hydroxylase CYP11B1, as well as other cytochrome P450 family members that occurred in a total of ~14% of samples in the discovery cohort (Supplemental Table 13 ).
Among known cancer genes, we observed that PIK3CA, which is recurrently mutated at a frequency of ~3% (20/667) in primary prostate cancers was not mutated in the AAPC discovery or extension cohorts (Fisher's Exact Test, p =0.0115; Figure 1 ) (10, 11, 30) . Previous analyses also suggest that PTEN is less commonly deleted in cohorts of men of African ancestry (2, 38) . Our data suggest that alteration of the PI3K signaling pathway either through PTEN deletion or PIK3CA mutation is a less common event in AAPC. Interestingly, we identified missense mutations in FOXA1 (F254V and H247L) in the AAPC cohort that occurred at the same residues only in men of African ancestry in the TCGA dataset (F254V and H247Y), raising the possibility of somatic mutations in prostate cancer that may be associated with ancestry (39) .
Finally, to test the addition of tumors from African-American men to a large cohort of primary prostate cancer largely from men of European ancestry, we performed a combined analysis of the AAPC discovery (n=102) and TCGA (n=457) cohorts which 
through an ETS transcriptional repressor. Furthermore, alteration of ERF may also be associated with more aggressive prostate cancers.
We observed a number of recurrent SCNAs that differed between the primary AAPC and TCGA cohorts. The limitations of this comparison with TCGA include differences in technologies (exome sequencing vs. SNP arrays) and stringencies for copy number detection. Still, our results, in conjunction with other studies that have examined specific copy number alterations, suggest that overall the somatic copy number alteration landscape may be distinct in primary prostate cancer in AfricanAmerican men. In addition, we find that alterations of the PI3K signaling pathway through deletion of PTEN or mutation of PIK3CA are uncommon in primary AAPC, suggesting that distinct patterns of genomic alterations may occur in this cohort with implications for precision medicine.
Our results suggest that increasing the ancestral diversity of study populations for cancer genomic characterization may help increase the discovery potential of these studies, which we believe to date have not included sufficiently large numbers of men from African ancestry. Given the relatively lower mutation rate of prostate cancer, larger cohorts of AA prostate cancer patients may be required to identify recurrently mutated genes that may contribute to prostate carcinogenesis or to aggressive prostate cancer features in this population. These studies will inform whether alterations in these genes may be enriched in certain ancestral groups.
Recent studies have implicated prostate tumor location, differential gene expression, and somatic genomic events such as LSAMP deletions in prostate cancers in AA men (2) (3) (4) (42) (43) (44) 
reasons for the aggressive nature of prostate cancer in AA men that is only partially explained by the genomic studies to date. Additional studies focused on metastatic CRPC samples from AA men and development of methodologies to integrate analyses of somatic and germline data may improve our understanding of the nature of aggressive prostate cancer in these patients (23, (45) (46) (47) . Our results suggest that inclusion of sufficient numbers of patients of African ancestry in cancer genomic studies may enable the discovery of new cancer genes and inform the inclusion of diverse populations towards precision cancer medicine (48) . Table 2 ). The extension cohort comprised samples from Karmanos Cancer Center, Johns Hopkins University/Prostate Cancer Biorepository Network (PCBN), and Roswell Park Cancer Institute (Supplemental Table 8 
METHODS
Cohort description and pathology evaluation. The discovery cohort comprised specimens from Weill Cornell Medicine (WCM) and Karmanos Cancer Center (Supplemental
ERF fluorescence in situ hybridization (FISH). To assess ERF deletion in tissues,
we developed a dual-color FISH assay consisting of a locus specific probe (W12-2967N22) plus reference probe spanning a stable region of the chromosome (RP11-46I12). All clones were tested on normal metaphase spreads of CGH target slides as previously described (9, 21) . ERF deletion was defined as the presence of 0 or 1 copies on average per nucleus compared to two reference signals. At least 100 nuclei were evaluated per tissue section using a fluorescence microscope (Olympus BX51; Olympus Optical, Tokyo, Japan).
ERF RNA in situ hybridization (RNAish).
This single-color chromogenic detection assay uses pairs of specially designed oligonucleotide probes that, through sequence-specific hybridization, recognize both the specific target ERF RNA sequence and the signal amplification system (see ERF Oligonucleotide list, Supplemental Table 14 ) (Affymetrix, Inc., Santa Clara, CA). 
Exome sequencing and analysis
For our WES discovery cohort we collected treatment-naïve radical prostatectomy specimens collected from two primary sites: New York City (Weill Cornell Medicine) and Detroit (Karmanos Cancer Institute/Wayne State University). All patients were self-reported African-American. All tissue DNA was extracted from formalin-fixed paraffin embedded (FFPE) tissues. We sequenced 128 matched tumor-normal pairs and after quality control for contamination and low tumor purity (Supplemental Table 15 
Somatic alterations, Filters, and Germline analysis
We used Mutect and the Indelocator (http://www.broadinstitute.org/cancer/cga/indelocator) for calling single nucleotide changes and insertion/deletions (Supplemental Methods). We used an FFPE filter to remove mutations likely from FFPE artifacts. We also used the GATK HaplotypeCaller to find germline variants within a specific gene.
Germline Variant Interpretation
The analysis of germline variants focused on variants identified among 20 genes that are associated with autosomal dominant cancer-predisposition syndromes. 
DNA sequencing validation
For validation, we used the Fluidigm Access Array microfluidic device. PCR products were barcoded, pooled and subjected to Illumina sequencing on a MiSeq instrument.
Cell Culture/Lentiviral transduction
LNCaP and PC3 cells were cultured in RPMI (Gibco) with 10% Fetal bovine serum. 
Western Blot Analysis
Cell lysates were prepared by lysing cells in 1% NP-40 with protease inhibitors (Roche) and phosphatase inhibitors (Calbiochem). Lysates were fractionated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes using the iBlot system (Life Technologies). Immunoblotting was performed using LI-COR reagents (Odyssey Blocking Buffer and IRDye 800CW and IRDye 680RD secondary antibodies) according to the manufacturer's instructions (LI-COR Biosciences). Fluorescence detection was performed using an Odyssey CLx Infrared Imaging System, and quantitation was performed using Image Studio software (LI-COR) Anti-ERF antibody was purchased from Abcam (ab61108).
Antibody for vinculin was purchased from Sigma (#V9131).
qRT-PCR
Total RNA was isolated using RNAeasy (Qiagen). cDNA was prepared using ~1ug of RNA and the Superscript III kit (Life technologies). ERF transcript levels were quantified using SYBR green (Applied Biosystems) and measured using Quantstudio 6. The following primers were used for ERF:
Research. Table 16 ) (50).
Soft Agar Assays
PC3 cells were transduced with lentivirus generated with pLKO-puro-shRNA plasmids. Twenty-four hours post-infection, cells were selected with 2ug/ml puromycin. After 48 hours of selection, cells were split for qRT-PCR assays and for passaging in normal serum-containing media for soft agar assays. 1 x 10 4 cells were 
Accession Numbers
The accession number for sequencing files is dbGAP: phs000945. Research.
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